Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Sclerosis | 57 | 2024 | 97 | 23.730 |
Why?
|
Immunologic Factors | 14 | 2021 | 27 | 4.450 |
Why?
|
Breast Feeding | 13 | 2020 | 133 | 4.400 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 14 | 2021 | 16 | 4.180 |
Why?
|
Pregnancy Complications | 14 | 2020 | 196 | 3.600 |
Why?
|
Rituximab | 14 | 2024 | 15 | 3.240 |
Why?
|
Humans | 91 | 2024 | 17611 | 2.970 |
Why?
|
Female | 68 | 2024 | 12608 | 2.420 |
Why?
|
Vitamin D | 5 | 2018 | 76 | 2.210 |
Why?
|
Postpartum Period | 8 | 2023 | 94 | 2.150 |
Why?
|
Neurology | 4 | 2021 | 6 | 2.110 |
Why?
|
Adult | 47 | 2024 | 7598 | 2.060 |
Why?
|
Vitamin D Deficiency | 4 | 2018 | 21 | 1.990 |
Why?
|
Male | 42 | 2024 | 10008 | 1.720 |
Why?
|
Retrospective Studies | 18 | 2024 | 2447 | 1.670 |
Why?
|
Pregnancy | 22 | 2023 | 1494 | 1.620 |
Why?
|
Recurrence | 9 | 2023 | 186 | 1.560 |
Why?
|
Middle Aged | 29 | 2024 | 7911 | 1.410 |
Why?
|
Young Adult | 19 | 2024 | 2427 | 1.400 |
Why?
|
Immunosuppressive Agents | 6 | 2023 | 20 | 1.300 |
Why?
|
Hispanic Americans | 7 | 2019 | 404 | 1.240 |
Why?
|
Sunlight | 2 | 2018 | 13 | 1.220 |
Why?
|
Abnormalities, Drug-Induced | 4 | 2016 | 15 | 1.200 |
Why?
|
Natalizumab | 10 | 2023 | 10 | 1.200 |
Why?
|
Glatiramer Acetate | 6 | 2020 | 6 | 1.180 |
Why?
|
Adrenal Cortex Hormones | 4 | 2022 | 68 | 1.170 |
Why?
|
Interferon-beta | 6 | 2020 | 6 | 1.130 |
Why?
|
Registries | 10 | 2023 | 471 | 1.120 |
Why?
|
Antibodies, Monoclonal | 6 | 2020 | 20 | 1.120 |
Why?
|
Ethnic Groups | 4 | 2014 | 485 | 1.080 |
Why?
|
Antibodies, Monoclonal, Humanized | 6 | 2020 | 24 | 1.070 |
Why?
|
Disease Progression | 4 | 2021 | 264 | 1.020 |
Why?
|
Demyelinating Autoimmune Diseases, CNS | 2 | 2015 | 7 | 0.990 |
Why?
|
Neuromyelitis Optica | 2 | 2021 | 2 | 0.970 |
Why?
|
Cohort Studies | 15 | 2023 | 2570 | 0.960 |
Why?
|
Hepatitis B Vaccines | 2 | 2015 | 43 | 0.960 |
Why?
|
Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 1 | 0.940 |
Why?
|
Phenotype | 1 | 2024 | 149 | 0.940 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 2 | 2022 | 12 | 0.930 |
Why?
|
Agammaglobulinemia | 1 | 2024 | 2 | 0.930 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 368 | 0.930 |
Why?
|
Drugs, Essential | 1 | 2023 | 1 | 0.920 |
Why?
|
Biosimilar Pharmaceuticals | 1 | 2023 | 1 | 0.920 |
Why?
|
Fingolimod Hydrochloride | 5 | 2023 | 5 | 0.910 |
Why?
|
Health Status Disparities | 2 | 2024 | 146 | 0.910 |
Why?
|
Disabled Persons | 2 | 2015 | 35 | 0.900 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 25 | 0.900 |
Why?
|
Papillomavirus Vaccines | 2 | 2015 | 113 | 0.880 |
Why?
|
Family | 1 | 2024 | 111 | 0.860 |
Why?
|
Vaccination | 3 | 2022 | 635 | 0.850 |
Why?
|
Pseudotumor Cerebri | 2 | 2013 | 3 | 0.850 |
Why?
|
Demyelinating Diseases | 2 | 2013 | 3 | 0.820 |
Why?
|
Infant, Newborn, Diseases | 2 | 2020 | 34 | 0.810 |
Why?
|
Incidence | 10 | 2024 | 1255 | 0.800 |
Why?
|
Pregnancy Outcome | 3 | 2023 | 154 | 0.800 |
Why?
|
Obesity | 3 | 2013 | 837 | 0.800 |
Why?
|
Vaccines | 2 | 2015 | 212 | 0.790 |
Why?
|
Access to Information | 1 | 2021 | 13 | 0.790 |
Why?
|
California | 12 | 2024 | 2284 | 0.780 |
Why?
|
Awards and Prizes | 1 | 2021 | 9 | 0.770 |
Why?
|
Cytokines | 2 | 2020 | 30 | 0.760 |
Why?
|
Social Determinants of Health | 1 | 2021 | 37 | 0.760 |
Why?
|
Withholding Treatment | 1 | 2021 | 26 | 0.740 |
Why?
|
Adolescent | 13 | 2024 | 3651 | 0.730 |
Why?
|
Nervous System Diseases | 3 | 2019 | 19 | 0.700 |
Why?
|
Betacoronavirus | 1 | 2020 | 35 | 0.700 |
Why?
|
Risk Factors | 10 | 2019 | 3325 | 0.690 |
Why?
|
Cognition Disorders | 1 | 2020 | 31 | 0.690 |
Why?
|
Coronavirus Infections | 1 | 2020 | 49 | 0.670 |
Why?
|
Gene-Environment Interaction | 1 | 2019 | 21 | 0.670 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 56 | 0.670 |
Why?
|
Quality Improvement | 1 | 2021 | 189 | 0.650 |
Why?
|
Risk | 6 | 2017 | 516 | 0.650 |
Why?
|
Environmental Exposure | 1 | 2019 | 116 | 0.630 |
Why?
|
Health Services Accessibility | 1 | 2021 | 289 | 0.620 |
Why?
|
Immunoglobulin G | 3 | 2024 | 29 | 0.620 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 4 | 0.610 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 62 | 0.600 |
Why?
|
African Continental Ancestry Group | 2 | 2018 | 162 | 0.600 |
Why?
|
Cytomegalovirus | 1 | 2017 | 3 | 0.590 |
Why?
|
Herpesvirus 4, Human | 1 | 2017 | 6 | 0.590 |
Why?
|
United States | 10 | 2023 | 3956 | 0.590 |
Why?
|
Child | 10 | 2023 | 2474 | 0.580 |
Why?
|
Antibodies, Viral | 1 | 2017 | 65 | 0.570 |
Why?
|
Medication Reconciliation | 2 | 2013 | 5 | 0.550 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2016 | 5 | 0.530 |
Why?
|
Case-Control Studies | 7 | 2021 | 1115 | 0.530 |
Why?
|
Estriol | 1 | 2015 | 2 | 0.530 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2006 | 2 | 0.530 |
Why?
|
Peptides | 2 | 2014 | 12 | 0.520 |
Why?
|
Prevalence | 7 | 2023 | 884 | 0.510 |
Why?
|
Disease Management | 2 | 2013 | 135 | 0.500 |
Why?
|
Emigration and Immigration | 1 | 2015 | 15 | 0.490 |
Why?
|
Crotonates | 1 | 2014 | 1 | 0.490 |
Why?
|
Toluidines | 1 | 2014 | 1 | 0.490 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 1322 | 0.470 |
Why?
|
Propylene Glycols | 1 | 2014 | 1 | 0.460 |
Why?
|
Sphingosine | 1 | 2014 | 1 | 0.460 |
Why?
|
Aged | 11 | 2024 | 6095 | 0.450 |
Why?
|
Continental Population Groups | 2 | 2013 | 302 | 0.450 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 103 | 0.450 |
Why?
|
Spinal Cord Injuries | 1 | 2013 | 5 | 0.450 |
Why?
|
Premature Birth | 4 | 2023 | 137 | 0.450 |
Why?
|
Hospital Mortality | 3 | 2022 | 145 | 0.440 |
Why?
|
Residence Characteristics | 2 | 2015 | 248 | 0.430 |
Why?
|
Hospitalization | 4 | 2022 | 797 | 0.430 |
Why?
|
Academies and Institutes | 2 | 2023 | 7 | 0.420 |
Why?
|
Interferon-gamma | 3 | 2010 | 8 | 0.410 |
Why?
|
T-Lymphocytes | 2 | 2010 | 8 | 0.390 |
Why?
|
Dietary Supplements | 3 | 2018 | 87 | 0.390 |
Why?
|
Prospective Studies | 6 | 2020 | 1267 | 0.390 |
Why?
|
Puerperal Disorders | 2 | 2020 | 9 | 0.380 |
Why?
|
Infant, Newborn | 8 | 2023 | 844 | 0.380 |
Why?
|
European Continental Ancestry Group | 4 | 2019 | 529 | 0.370 |
Why?
|
Milk, Human | 2 | 2020 | 7 | 0.360 |
Why?
|
Infant | 6 | 2024 | 1171 | 0.350 |
Why?
|
Autoimmune Diseases | 1 | 2010 | 20 | 0.350 |
Why?
|
Immune Tolerance | 1 | 2010 | 6 | 0.350 |
Why?
|
Pregnancy Trimesters | 1 | 2010 | 30 | 0.340 |
Why?
|
Clinical Trials as Topic | 3 | 2012 | 130 | 0.340 |
Why?
|
Aquaporin 4 | 1 | 2009 | 2 | 0.340 |
Why?
|
Diet | 2 | 2022 | 365 | 0.330 |
Why?
|
Patient Selection | 2 | 2012 | 190 | 0.330 |
Why?
|
Socioeconomic Factors | 3 | 2017 | 630 | 0.330 |
Why?
|
Age Factors | 3 | 2020 | 917 | 0.320 |
Why?
|
Time Factors | 4 | 2020 | 1086 | 0.320 |
Why?
|
JC Virus | 2 | 2006 | 2 | 0.320 |
Why?
|
Integrin alpha4 | 2 | 2006 | 2 | 0.320 |
Why?
|
African Americans | 3 | 2021 | 472 | 0.310 |
Why?
|
HLA-DRB1 Chains | 2 | 2019 | 13 | 0.310 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 3 | 2002 | 3 | 0.300 |
Why?
|
Prognosis | 3 | 2021 | 606 | 0.280 |
Why?
|
Disability Evaluation | 3 | 2015 | 46 | 0.270 |
Why?
|
Neurotoxicity Syndromes | 1 | 2006 | 3 | 0.270 |
Why?
|
Child, Preschool | 5 | 2014 | 1409 | 0.270 |
Why?
|
Lactation | 2 | 2020 | 52 | 0.250 |
Why?
|
Abortion, Spontaneous | 2 | 2016 | 47 | 0.250 |
Why?
|
Opportunistic Infections | 1 | 2005 | 7 | 0.250 |
Why?
|
Longitudinal Studies | 3 | 2013 | 710 | 0.250 |
Why?
|
Teratoma | 1 | 2024 | 1 | 0.240 |
Why?
|
Sweden | 5 | 2021 | 19 | 0.220 |
Why?
|
Cognitive Dysfunction | 1 | 2024 | 47 | 0.220 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 49 | 0.220 |
Why?
|
Respiratory Insufficiency | 1 | 2023 | 17 | 0.220 |
Why?
|
Noninvasive Ventilation | 1 | 2023 | 11 | 0.220 |
Why?
|
Blindness | 1 | 2022 | 5 | 0.210 |
Why?
|
Dexamethasone | 1 | 2022 | 12 | 0.210 |
Why?
|
Treatment Outcome | 3 | 2020 | 1259 | 0.210 |
Why?
|
Infusions, Intravenous | 2 | 2021 | 10 | 0.210 |
Why?
|
Sex Factors | 2 | 2020 | 643 | 0.210 |
Why?
|
Pregnancy, Animal | 1 | 2002 | 1 | 0.210 |
Why?
|
Suppressor Factors, Immunologic | 1 | 2002 | 1 | 0.210 |
Why?
|
Food | 1 | 2022 | 30 | 0.210 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2019 | 6 | 0.210 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2011 | 3 | 0.200 |
Why?
|
Bibliometrics | 1 | 2021 | 3 | 0.200 |
Why?
|
Surveys and Questionnaires | 2 | 2017 | 1309 | 0.200 |
Why?
|
Risk Assessment | 2 | 2021 | 1097 | 0.200 |
Why?
|
Medical Records | 2 | 2019 | 100 | 0.200 |
Why?
|
Logistic Models | 2 | 2017 | 926 | 0.200 |
Why?
|
Pandemics | 2 | 2022 | 287 | 0.190 |
Why?
|
Alleles | 2 | 2019 | 84 | 0.190 |
Why?
|
Educational Status | 2 | 2020 | 200 | 0.190 |
Why?
|
Leadership | 1 | 2021 | 39 | 0.190 |
Why?
|
Seasons | 2 | 2012 | 102 | 0.190 |
Why?
|
Brain | 3 | 2013 | 45 | 0.190 |
Why?
|
Body Mass Index | 2 | 2018 | 958 | 0.190 |
Why?
|
Diet Surveys | 1 | 2021 | 57 | 0.180 |
Why?
|
Disease Susceptibility | 2 | 2016 | 37 | 0.180 |
Why?
|
Fruit | 1 | 2021 | 79 | 0.180 |
Why?
|
Algorithms | 2 | 2019 | 233 | 0.180 |
Why?
|
Early Medical Intervention | 1 | 2020 | 10 | 0.180 |
Why?
|
Verbal Behavior | 1 | 2020 | 2 | 0.180 |
Why?
|
Psychomotor Performance | 1 | 2020 | 4 | 0.180 |
Why?
|
Follow-Up Studies | 3 | 2020 | 1210 | 0.180 |
Why?
|
Neuropsychological Tests | 1 | 2020 | 38 | 0.170 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2019 | 373 | 0.170 |
Why?
|
Severity of Illness Index | 1 | 2021 | 454 | 0.170 |
Why?
|
Feeding Behavior | 1 | 2021 | 166 | 0.170 |
Why?
|
Child Development | 1 | 2020 | 54 | 0.170 |
Why?
|
Family Planning Services | 1 | 2019 | 20 | 0.170 |
Why?
|
Secondary Prevention | 2 | 2014 | 47 | 0.160 |
Why?
|
Pharmacoepidemiology | 1 | 2019 | 18 | 0.160 |
Why?
|
Pregnancy Trimester, Third | 2 | 2020 | 17 | 0.160 |
Why?
|
Chronic Disease | 2 | 2021 | 428 | 0.160 |
Why?
|
Transcription Factors | 1 | 2019 | 19 | 0.160 |
Why?
|
Models, Theoretical | 1 | 2019 | 70 | 0.160 |
Why?
|
Primary Health Care | 1 | 2024 | 766 | 0.150 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2018 | 3 | 0.150 |
Why?
|
Ultraviolet Rays | 1 | 2018 | 6 | 0.150 |
Why?
|
Genotyping Techniques | 1 | 2018 | 26 | 0.150 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2020 | 160 | 0.150 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2017 | 2 | 0.150 |
Why?
|
Hygiene | 1 | 2017 | 4 | 0.150 |
Why?
|
Genotype | 1 | 2018 | 227 | 0.150 |
Why?
|
Reproductive Physiological Phenomena | 1 | 2017 | 3 | 0.150 |
Why?
|
Regression Analysis | 2 | 2019 | 297 | 0.150 |
Why?
|
Emigrants and Immigrants | 1 | 2017 | 27 | 0.140 |
Why?
|
Smoking | 1 | 2019 | 483 | 0.140 |
Why?
|
Analysis of Variance | 2 | 2015 | 159 | 0.130 |
Why?
|
Progestins | 1 | 2016 | 25 | 0.130 |
Why?
|
Societies, Medical | 2 | 2013 | 74 | 0.130 |
Why?
|
Body Height | 1 | 2016 | 62 | 0.130 |
Why?
|
Pregnancy Trimester, First | 1 | 2016 | 39 | 0.130 |
Why?
|
Cesarean Section | 1 | 2016 | 30 | 0.130 |
Why?
|
Neoplasms | 1 | 2020 | 438 | 0.120 |
Why?
|
Databases, Factual | 2 | 2019 | 309 | 0.120 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2014 | 2 | 0.120 |
Why?
|
Colitis, Ulcerative | 1 | 2014 | 9 | 0.120 |
Why?
|
Crohn Disease | 1 | 2014 | 14 | 0.120 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 50 | 0.110 |
Why?
|
Prepaid Health Plans | 1 | 2013 | 20 | 0.110 |
Why?
|
B-Lymphocytes | 2 | 2011 | 4 | 0.100 |
Why?
|
Animals | 4 | 2014 | 259 | 0.100 |
Why?
|
Censuses | 1 | 2012 | 31 | 0.100 |
Why?
|
Odds Ratio | 2 | 2010 | 671 | 0.100 |
Why?
|
Hydroxycholecalciferols | 1 | 2010 | 2 | 0.090 |
Why?
|
Prenatal Nutritional Physiological Phenomena | 1 | 2010 | 5 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2002 | 27 | 0.090 |
Why?
|
Birth Certificates | 1 | 2010 | 22 | 0.090 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 85 | 0.090 |
Why?
|
Vitamins | 1 | 2010 | 64 | 0.090 |
Why?
|
Amenorrhea | 1 | 2010 | 3 | 0.090 |
Why?
|
Cell Count | 1 | 2010 | 10 | 0.090 |
Why?
|
Down-Regulation | 1 | 2010 | 13 | 0.090 |
Why?
|
Cell Proliferation | 1 | 2010 | 19 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2010 | 13 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 27 | 0.090 |
Why?
|
Overweight | 1 | 2012 | 269 | 0.090 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 351 | 0.090 |
Why?
|
Population Surveillance | 1 | 2011 | 263 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 129 | 0.080 |
Why?
|
Aged, 80 and over | 1 | 2014 | 1900 | 0.080 |
Why?
|
Health Maintenance Organizations | 1 | 2010 | 417 | 0.080 |
Why?
|
Mice | 3 | 2002 | 68 | 0.070 |
Why?
|
Anal Canal | 1 | 2006 | 7 | 0.070 |
Why?
|
Age of Onset | 1 | 2006 | 79 | 0.070 |
Why?
|
Cell Migration Inhibition | 1 | 2006 | 1 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 77 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2006 | 4 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 60 | 0.070 |
Why?
|
Germany | 2 | 2016 | 14 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2006 | 28 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 531 | 0.060 |
Why?
|
Antigens, CD20 | 2 | 2020 | 2 | 0.060 |
Why?
|
Aphasia | 1 | 2005 | 1 | 0.060 |
Why?
|
Cytarabine | 1 | 2005 | 1 | 0.060 |
Why?
|
Ataxia | 1 | 2005 | 2 | 0.060 |
Why?
|
Paresis | 1 | 2005 | 4 | 0.060 |
Why?
|
Mice, Inbred Strains | 2 | 2002 | 4 | 0.060 |
Why?
|
Amino Acid Sequence | 2 | 2002 | 9 | 0.060 |
Why?
|
Molecular Sequence Data | 2 | 2002 | 17 | 0.060 |
Why?
|
Mitoxantrone | 1 | 2004 | 2 | 0.060 |
Why?
|
Computers, Handheld | 1 | 2024 | 11 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2005 | 94 | 0.060 |
Why?
|
Stakeholder Participation | 1 | 2024 | 21 | 0.060 |
Why?
|
Research Design | 1 | 2006 | 374 | 0.060 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2024 | 57 | 0.060 |
Why?
|
Periaqueductal Gray | 1 | 2003 | 1 | 0.060 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 1 | 0.060 |
Why?
|
Aspartic Acid | 1 | 2003 | 2 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2003 | 5 | 0.060 |
Why?
|
Oxygen | 1 | 2023 | 16 | 0.050 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 11 | 0.050 |
Why?
|
Placenta | 1 | 2023 | 20 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2023 | 37 | 0.050 |
Why?
|
Population Control | 1 | 2022 | 1 | 0.050 |
Why?
|
Dysgammaglobulinemia | 1 | 2002 | 1 | 0.050 |
Why?
|
Th1 Cells | 1 | 2002 | 1 | 0.050 |
Why?
|
Myelin Proteolipid Protein | 1 | 2002 | 1 | 0.050 |
Why?
|
Adoptive Transfer | 1 | 2002 | 1 | 0.050 |
Why?
|
Autoantigens | 1 | 2002 | 2 | 0.050 |
Why?
|
Interleukin-2 | 1 | 2002 | 3 | 0.050 |
Why?
|
Cell Movement | 1 | 2002 | 5 | 0.050 |
Why?
|
Transforming Growth Factor beta | 1 | 2002 | 8 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2002 | 7 | 0.050 |
Why?
|
Interleukin-17 | 1 | 2002 | 1 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2002 | 17 | 0.050 |
Why?
|
Dementia | 1 | 2024 | 106 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2002 | 23 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2002 | 25 | 0.050 |
Why?
|
Medicare | 1 | 2023 | 202 | 0.050 |
Why?
|
Anticoagulants | 1 | 2022 | 127 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 98 | 0.050 |
Why?
|
Epitopes | 1 | 1999 | 4 | 0.040 |
Why?
|
Ligands | 1 | 1999 | 6 | 0.040 |
Why?
|
Bacterial Proteins | 1 | 1999 | 13 | 0.040 |
Why?
|
Immunotherapy | 1 | 2019 | 6 | 0.040 |
Why?
|
Geography, Medical | 1 | 2019 | 4 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 11 | 0.040 |
Why?
|
HLA-A3 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
HLA-B7 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
Observer Variation | 1 | 2019 | 37 | 0.040 |
Why?
|
Haplotypes | 1 | 2019 | 34 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 304 | 0.040 |
Why?
|
Asian Americans | 1 | 2019 | 176 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 243 | 0.040 |
Why?
|
Insurance, Health | 1 | 2019 | 181 | 0.040 |
Why?
|
Anemia, Neonatal | 1 | 2014 | 1 | 0.030 |
Why?
|
Leukocytosis | 1 | 2014 | 5 | 0.030 |
Why?
|
Fetal Blood | 1 | 2014 | 13 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2014 | 15 | 0.030 |
Why?
|
Fetal Membranes, Premature Rupture | 1 | 2014 | 11 | 0.030 |
Why?
|
Gestational Age | 1 | 2014 | 111 | 0.030 |
Why?
|
Infant, Small for Gestational Age | 1 | 2014 | 57 | 0.030 |
Why?
|
Mothers | 1 | 2014 | 105 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2011 | 3 | 0.020 |
Why?
|
Family Characteristics | 1 | 2012 | 54 | 0.020 |
Why?
|
Income | 1 | 2012 | 90 | 0.020 |
Why?
|
Health Planning | 1 | 2010 | 16 | 0.020 |
Why?
|
Data Collection | 1 | 2012 | 256 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 45 | 0.020 |
Why?
|
Health Services Research | 1 | 2012 | 231 | 0.020 |
Why?
|
Poverty | 1 | 2012 | 166 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 237 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2010 | 201 | 0.020 |
Why?
|
Gadolinium | 1 | 2008 | 1 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2008 | 3 | 0.020 |
Why?
|
Remission Induction | 1 | 2008 | 25 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2008 | 155 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2010 | 415 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 2003 | 8 | 0.010 |
Why?
|
Receptors, Fc | 1 | 2002 | 1 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2002 | 7 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 4 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2002 | 17 | 0.010 |
Why?
|
Autopsy | 1 | 2002 | 15 | 0.010 |
Why?
|
Inflammation | 1 | 2002 | 62 | 0.010 |
Why?
|
Acute Disease | 1 | 2002 | 142 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2002 | 381 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1999 | 1 | 0.010 |
Why?
|
Cell Division | 1 | 1999 | 5 | 0.010 |
Why?
|
Interleukin-4 | 1 | 1999 | 4 | 0.010 |
Why?
|
Myelin Basic Protein | 1 | 1999 | 5 | 0.010 |
Why?
|